# Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

> **NCT03131037** · PHASE1 · COMPLETED · sponsor: **Candel Therapeutics, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** CAN-2409 + valacyclovir

## Key facts

- **NCT ID:** NCT03131037
- **Lead sponsor:** Candel Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-04
- **Primary completion:** 2021-12-01
- **Final completion:** 2023-09-20
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03131037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03131037, "Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03131037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*